First, we classified our patients into NL and NAFLD, and we observed that the hepatic relative mRNA expression of SFRP5 was higher in the NAFLD group than in NL subjects (Figure 3A). Here, SFRP5 is linked to metabolic dysfunction-associated steatotic liver disease.